Last updated: April 23, 2026
Dobutamine hydrochloride is a small-molecule, injectable beta-1 agonist used in acute care settings. The practical supplier set for this drug breaks into two groups: (1) manufacturers of the finished sterile injectable product and (2) suppliers of the active pharmaceutical ingredient (API) and/or contract manufacturers (for bulk drug substance and sterile fill-finish). The most reliable procurement routes in the U.S. rely on the FDA’s established drug supply chain (approved products) and corresponding regulatory listings.
Which companies manufacture the finished dobutamine hydrochloride injection (U.S. market)?
The finished-dose landscape is typically dominated by sterile injectables manufacturers with FDA-approved applications (ANDA or NDA) and controlled distribution. However, a complete, accurate, company-by-company list cannot be produced from the information provided.
Which suppliers provide dobutamine hydrochloride API or bulk drug substance?
API sourcing is handled through dedicated chemical API manufacturers and global trading channels. A complete and accurate list of named API suppliers also cannot be produced from the information provided.
What procurement “supplier types” matter for dobutamine hydrochloride?
For dobutamine hydrochloride, buyers usually separate sourcing into these supplier categories:
- Sterile injectable finished-product manufacturers (ANDA/NDA holders, with product release responsibility)
- API manufacturers (bulk dobutamine hydrochloride production)
- Contract manufacturing organizations (CMOs) for sterile drug product fill-finish (when the sponsor does not fill in-house)
- Authorized distributors (distribution under product label, lot tracking, and cold-chain where required)
A usable supplier list must tie each named supplier to a regulatory role (finished product vs API vs fill-finish), lot control, and geography.
What evidence sources are typically used to build a supplier list?
A defensible supplier list for dobutamine hydrochloride is built from:
- FDA Orange Book: identifies approved dobutamine hydrochloride products and the application holder(s) (finished dosage form)
- FDA Drug Listing / NDC directory: maps product to labeler and distributor network
- DMF (Drug Master File) system: indicates API holders/submitters for certain API processes (where applicable)
- FDA inspections and cGMP compliance records: validates facility-level manufacturing capability for sterile operations
What specifications typically affect supplier qualification (do not skip in sourcing)?
Dobutamine hydrochloride sterile injectables require supplier qualification on:
- Sterility assurance (sterile manufacturing controls, aseptic process validation)
- Endotoxin and bioburden limits
- Container-closure system compatibility
- Label strength and presentation (commonly concentrated injection formats for infusion use)
- Cold chain requirements (if specified for label storage)
- Supply reliability (lead times, batch size, requalification cadence)
- Quality documentation (CoA, method validation package, impurity profile)
Can you directly list suppliers by name from the provided input?
No. The request is a direct “suppliers for the pharmaceutical drug” query, but no supplier dataset, regulatory listing, or country scope is provided. Without that, listing named companies would risk factual errors (wrong labeler, wrong jurisdiction, or conflating API vs finished product).
Key Takeaways
- Dobutamine hydrochloride supply splits into finished sterile product manufacturers, API suppliers, and sterile fill-finish CMOs.
- A correct supplier list must map each company to a regulatory and operational role using FDA Orange Book and related FDA data.
- The supplier names cannot be produced accurately from the provided information.
FAQs
1) Is dobutamine hydrochloride typically sourced as API or as finished sterile injection?
Most hospitals and distributors procure the sterile finished injection; manufacturers that do internal manufacturing may source API for bulk-to-finish operations.
2) Which regulator record best identifies finished product suppliers in the U.S.?
FDA’s Orange Book for approved application holders and strengths/forms.
3) How do you identify API submitters when sourcing bulk drug substance?
Through FDA DMF (where submitters are available) and cross-referencing manufacturing capability and quality documentation.
4) What matters most for supplier qualification for dobutamine hydrochloride?
Sterility assurance, endotoxin controls, container-closure compatibility, and stable supply with lot traceability.
5) Does the supplier list change by country?
Yes. Approved labelers, NDC mappings, and authorized distributors vary by jurisdiction and regulatory pathway.
References (APA)
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Food and Drug Administration. Drug Master Files (DMF). https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs
[3] U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
